{"id":"cisplatin-5fu-afatinib","safety":{"commonSideEffects":["diarrhea","rash","nausea","vomiting","neutropenia","mucositis","nephrotoxicity","neuropathy"],"contraindications":["severe renal impairment","severe hepatic impairment","pregnancy"]},"_chembl":{"chemblId":"CHEMBL2105712","moleculeType":"Small molecule","molecularWeight":"718.09"},"_fixedAt":"2026-03-30T14:22:08.785555","modality":"Small molecule","_dailymed":null,"mechanism":{"target":"EGFR, HER2, DNA","modality":"Small Molecule","explanation":"Cisplatin forms DNA crosslinks causing apoptosis, while 5-fluorouracil inhibits thymidylate synthase blocking DNA synthesis. Afatinib irreversibly blocks EGFR and HER2 signaling pathways, inhibiting tumor cell proliferation and survival. The combination aims to provide synergistic anti-tumor activity through multiple mechanisms.","oneSentence":"Combines platinum-based DNA crosslinking and pyrimidine analog chemotherapy with irreversible EGFR/HER2 tyrosine kinase inhibition."},"_scrapedAt":"2026-03-28T02:30:46.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122820,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"cetuximab plus chemotherapy","brand":"Erbitux","company":"Eli Lilly","rationale":"EGFR-targeted therapy combined with chemotherapy for solid tumors"},{"name":"erlotinib","brand":"Tarceva","company":"Genentech","rationale":"EGFR tyrosine kinase inhibitor for EGFR-mutant cancers"},{"name":"gefitinib","brand":"Iressa","company":"AstraZeneca","rationale":"First-generation EGFR tyrosine kinase inhibitor"}],"description":"Cisplatin-5FU-Afatinib is an investigational combination therapy being studied by the Hellenic Cooperative Oncology Group in Phase 2 trials. It combines the chemotherapy agents cisplatin and 5-fluorouracil (5FU) with afatinib, an EGFR/HER2 tyrosine kinase inhibitor, for potential treatment of solid tumors.","indications":{"approved":[{"status":"investigational","condition":"Solid tumors","patientPopulation":"Adult, line of therapy unknown"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT00716417","phase":"PHASE1","title":"Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07-01","conditions":"Neoplasms","enrollment":47},{"nctId":"NCT01743365","phase":"PHASE2","title":"Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2013-02-11","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cisplatin-5FU-Afatinib","genericName":"Cisplatin-5FU-Afatinib","companyName":"Hellenic Cooperative Oncology Group","companyId":"hellenic-cooperative-oncology-group","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}